Literature DB >> 35719175

ACOG and local diagnostic criteria for hypertensive disorders of pregnancy (HDP) in La Paz-El Alto, Bolivia: A retrospective case-control study.

Litzi Lazo-Vega1, Lilian Toledo-Jaldin1, Abraham Badner1, José Luis Barriga-Vera2, Melany Castro-Monrroy3, Anna G Euser4, Alison Larrea-Alvarado1, Ian Lawrence5, Carola Mérida3, Rodrigo Mizutani2, Yuri Pérez6, Sebastian Rocabado7, Manfredo Vargas2, Vikram Vasan8, Colleen G Julian9, Lorna G Moore4.   

Abstract

Background: Hypertensive disorders of pregnancy (HDP) are a leading cause of maternal death in low- to middle-income countries (LMIC). The American College of Obstetricians and Gynecologists (ACOG) updated diagnostic guidelines to align signs and symptoms with those associated with maternal death. We performed an observational study to ask whether ACOG guidelines were employed and associated with adverse outcomes in La Paz-El Alto, Bolivia, an LMIC.
Methods: Medical records for all HDP discharge diagnoses (n = 734) and twice as many controls (n = 1647) were reviewed for one year at the three largest delivery sites. For the 690 cases and 1548 controls meeting inclusion criteria (singleton, 18-45 maternal age, local residence), health history, blood pressures, symptoms, lab tests, HDP diagnoses (i.e., gestational hypertension [GH]; preeclampsia [PE]; haemolysis, low platelets, high liver enzymes [HELLP] syndrome, eclampsia), and adverse outcomes were recorded. Bolivian diagnoses were compared to ACOG guidelines using accuracy analysis and associated with adverse outcomes by logistic regression. Findings: Both systems agreed with respect to eclampsia, but only 27% of all Bolivian HDP diagnoses met ACOG criteria. HDP increased adverse maternal- or perinatal-outcome risks for both systems, but ACOG guidelines enabled more pre-delivery diagnoses, graded maternal-risk assessment, and targeting of HDP terminating in maternal death. Interpretation: Bolivia diagnoses agreed with ACOG guidelines concerning end-stage disease (eclampsia) but not the other HDP due mainly to ACOG's recognition of a broader range of severe features. ACOG guidelines can aid in identifying pregnancies at greatest risk in LMICs, where most maternal and perinatal deaths occur. Funding: NIH TW010797, HD088590, HL138181, UL1 TR002535.

Entities:  

Keywords:  Eclampsia; HELLP syndrome; High altitude; Maternal mortality; Perinatal mortality; Preeclampsia

Year:  2022        PMID: 35719175      PMCID: PMC9205446          DOI: 10.1016/j.lana.2022.100194

Source DB:  PubMed          Journal:  Lancet Reg Health Am        ISSN: 2667-193X


  27 in total

1.  Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model.

Authors:  Peter von Dadelszen; Beth Payne; Jing Li; J Mark Ansermino; Fiona Broughton Pipkin; Anne-Marie Côté; M Joanne Douglas; Andrée Gruslin; Jennifer A Hutcheon; K S Joseph; Phillipa M Kyle; Tang Lee; Pamela Loughna; Jennifer M Menzies; Mario Merialdi; Alexandra L Millman; M Peter Moore; Jean-Marie Moutquin; Annie B Ouellet; Graeme N Smith; James J Walker; Keith R Walley; Barry N Walters; Mariana Widmer; Shoo K Lee; James A Russell; Laura A Magee
Journal:  Lancet       Date:  2010-12-23       Impact factor: 79.321

2.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  J Clin Epidemiol       Date:  2008-04       Impact factor: 6.437

Review 3.  Global and regional estimates of preeclampsia and eclampsia: a systematic review.

Authors:  Edgardo Abalos; Cristina Cuesta; Ana L Grosso; Doris Chou; Lale Say
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2013-06-07       Impact factor: 2.435

4.  Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222.

Authors: 
Journal:  Obstet Gynecol       Date:  2020-06       Impact factor: 7.661

Review 5.  Vascular Dysfunction in Mother and Offspring During Preeclampsia: Contributions from Latin-American Countries.

Authors:  Fernanda Regina Giachini; Carlos Galaviz-Hernandez; Alicia E Damiano; Marta Viana; Angela Cadavid; Patricia Asturizaga; Enrique Teran; Sonia Clapes; Martin Alcala; Julio Bueno; María Calderón-Domínguez; María P Ramos; Victor Vitorino Lima; Martha Sosa-Macias; Nora Martinez; James M Roberts; Carlos Escudero
Journal:  Curr Hypertens Rep       Date:  2017-10-06       Impact factor: 5.369

6.  4 million neonatal deaths: when? Where? Why?

Authors:  Joy E Lawn; Simon Cousens; Jelka Zupan
Journal:  Lancet       Date:  2005 Mar 5-11       Impact factor: 79.321

Review 7.  Methodological and technical issues related to the diagnosis, screening, prevention, and treatment of pre-eclampsia and eclampsia.

Authors:  J Villar; L Say; A Shennan; M Lindheimer; L Duley; A Conde-Agudelo; M Merialdi
Journal:  Int J Gynaecol Obstet       Date:  2004-06       Impact factor: 3.561

8.  Pre-eclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization Multicountry Survey on Maternal and Newborn Health.

Authors:  E Abalos; C Cuesta; G Carroli; Z Qureshi; M Widmer; J P Vogel; J P Souza
Journal:  BJOG       Date:  2014-03       Impact factor: 6.531

9.  High-altitude residence alters blood-pressure course and increases hypertensive disorders of pregnancy.

Authors:  Beth Bailey; Anna G Euser; Kirk A Bol; Colleen G Julian; Lorna G Moore
Journal:  J Matern Fetal Neonatal Med       Date:  2020-03-30

10.  Risk factors of pre-eclampsia/eclampsia and its adverse outcomes in low- and middle-income countries: a WHO secondary analysis.

Authors:  Ver Luanni Bilano; Erika Ota; Togoobaatar Ganchimeg; Rintaro Mori; João Paulo Souza
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.